CLRB

Cellectar Biosciences, Inc.

2.93 USD
+0.07 (+2.45%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Cellectar Biosciences, Inc. stock is down -5.79% since 30 days ago. The next earnings date is Aug 12, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 5 June’s closed higher than May.

About Cellectar Biosciences, Inc.

Cellectar Biosciences, Inc. focuses on the discovery, development, and commercialization of drugs for cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies.